Yann Chong Tan, Nuevocor CEO
May 6, 2025 01:00 AM EDT
Financing
Startups
Cell/Gene Tx

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

Kyle LaHucik

Senior Reporter

A Sin­ga­pore-based start­up raised a $45 mil­lion Se­ries B to start test­ing a gene ther­a­py in hu­mans next year for a ge­net­ic heart mus­cle dis­or­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times